- On 4 August 2026, Adyen N.V. announced it will power payment services for LillyDirect, supporting prescribed patients’ access to Eli Lilly’s FDA-approved medicines with flexible options such as cards, digital wallets, and HSA/FSA payments, underpinned by its fraud prevention, reconciliation, analytics, and AI-driven Intelligent Payment Routing.
- This collaboration highlights Adyen’s capabilities in complex, high-compliance healthcare payments and showcases how its scalable platform can support evolving patient and provider needs.
- We’ll now examine how Adyen’s role in LillyDirect’s healthcare-focused payments platform shapes its investment narrative, particularly around AI-enabled Intelligent Routing.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Adyen Investment Narrative Recap
To own Adyen, you need to believe its unified, global payments stack and higher margin value added services can offset competitive and macro pressures. The LillyDirect deal underlines Adyen’s ability to handle complex, high compliance verticals like healthcare, but it does not materially change the near term focus on execution in large enterprise wins or the key risks around competition, regulation and pricing pressure.
Among recent updates, Adyen’s June 2026 launch of Agentic Commerce feels particularly relevant. Both Agentic and Intelligent Payment Routing for LillyDirect lean on AI driven orchestration to keep Adyen embedded in complex payment flows. For investors tracking catalysts, these products sit at the heart of the debate over whether Adyen can deepen monetization per client fast enough to justify its premium valuation and offset slower share gains elsewhere.
Yet beneath the appeal of AI powered payment wins, there is a less obvious risk that investors should be aware of around rising compliance costs and...
Read the full narrative on Adyen (it's free!)
Adyen's narrative projects €4.1 billion revenue and €1.8 billion earnings by 2029. This requires 20.4% yearly revenue growth and about a €0.7 billion earnings increase from €1.1 billion today.
Uncover how Adyen's forecasts yield a €1330 fair value, a 43% upside to its current price.
Exploring Other Perspectives
Lowest estimate analysts paint a far more cautious picture, assuming about €4.2 billion in revenue and €1.8 billion in earnings by 2029, while warning that rising compliance burdens in tightly regulated areas like healthcare payments could curb margins. This LillyDirect news may eventually prompt both the consensus and the more pessimistic camp to reassess how much Adyen’s AI led products can offset those headwinds.
Explore 8 other fair value estimates on Adyen - why the stock might be worth just €974.81!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Adyen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Adyen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adyen's overall financial health at a glance.
Interested In Other Possibilities?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com